TrialCompass TCL
Back to results
Phase 1, Phase 2RecruitingPriority 2 · High priorityNCT07523555

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

ClinicalTrials.gov

Plain-language summary

This Phase 1, Phase 2 trial is comparing Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, and other medications against other options for people whose T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years to 75 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)
  • May require specific number of prior treatments

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Autologous CD19/CD22 dual-target CAR-T module (BIOLOGICAL): Biological: Autologous CD19/CD22 dual-target CAR-T module after lymphodepletion with fludarabine/cyclophosphamide. | Autologous CD19/CD20 dual-target CAR-T module (BIOLOGICAL): Biological: Autologous CD19/CD20 dual-target CAR-T module after lymphodepletion with fludarabine/cyclophosphamide. | Autologous BCMA/CD19 dual-target CAR-T module (BIOLOGICAL): Biological: Autologous BCMA/CD19 dual-target CAR-T module after lymphodepletion with fludarabine/cyclophosphamide. | Autologous BCMA/CD38 dual-target CAR-T module (BIOLOGICAL): Biological: Autologous BCMA/CD38 dual-target CAR-T module after lymphodepletion with fludarabine/cyclophosphamide. | Autologous BCMA/GPRC5D dual-target CAR-T (BIOLOGICAL): Biological: Autologous BCMA/GPRC5D dual-target CAR-T module after lymphodepletion with fludarabine/cyclophosphamide | Autologous CD33/CD123 dual-target CAR-T module (BIOLOGICAL): Biological: Autologous CD33/CD123 dual-target CAR-T module (simultaneous or planned sequential paired infusion, module-specific) after lymphodepletion. | Autologous CD33/CLL1 dual-target CAR-T module (BIOLOGICAL): Biological: Autologous CD33/CLL1 dual-target CAR-T module after lymphodepletion with fludarabine/cyclophosphamide. | Autologous CD5/CD7 dual-target CAR-T module (BIOLOGICAL): Biological: Autologous CD5/CD7 dual-target CAR-T module (including sequential paired infusion if needed for manufacturing/safety) after lymphodepletion.

Drugs / treatments
Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual-target CAR-T module, Autologous BCMA/CD38 dual-target CAR-T module, Autologous BCMA/GPRC5D dual-target CAR-T, Autologous CD33/CD123 dual-target CAR-T module, Autologous CD33/CLL1 dual-target CAR-T module, Autologous CD5/CD7 dual-target CAR-T module
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

NCT07523555

Phase: Phase 1, Phase 2 | Status: Recruiting | Priority: High

Plain-language summary

This Phase 1, Phase 2 trial is comparing Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, and other medications against other options for people whose T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

Who can join

  • Age 18 Years to 75 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)
  • May require specific number of prior treatments

What's being tested

Autologous CD19/CD22 dual-target CAR-T module (BIOLOGICAL): Biological: Autologous CD19/CD22 dual-target CAR-T module after lymphodepletion with fludarabine/cyclophosphamide. | Autologous CD19/CD20 dual-target CAR-T module (BIOLOGICAL): Biological: Autologous CD19/CD20 dual-target CAR-T module after lymphodepletion with fludarabine/cyclophosphamide. | Autologous BCMA/CD19 dual-target CAR-T module (BIOLOGICAL): Biological: Autologous BCMA/CD19 dual-target CAR-T module after lymphodepletion with fludarabine/cyclophosphamide. | Autologous BCMA/CD38 dual-target CAR-T module (BIOLOGICAL): Biological: Autologous BCMA/CD38 dual-target CAR-T module after lymphodepletion with fludarabine/cyclophosphamide. | Autologous BCMA/GPRC5D dual-target CAR-T (BIOLOGICAL): Biological: Autologous BCMA/GPRC5D dual-target CAR-T module after lymphodepletion with fludarabine/cyclophosphamide | Autologous CD33/CD123 dual-target CAR-T module (BIOLOGICAL): Biological: Autologous CD33/CD123 dual-target CAR-T module (simultaneous or planned sequential paired infusion, module-specific) after lymphodepletion. | Autologous CD33/CLL1 dual-target CAR-T module (BIOLOGICAL): Biological: Autologous CD33/CLL1 dual-target CAR-T module after lymphodepletion with fludarabine/cyclophosphamide. | Autologous CD5/CD7 dual-target CAR-T module (BIOLOGICAL): Biological: Autologous CD5/CD7 dual-target CAR-T module (including sequential paired infusion if needed for manufacturing/safety) after lymphodepletion.

Drugs / treatments: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual-target CAR-T module, Autologous BCMA/CD38 dual-target CAR-T module, Autologous BCMA/GPRC5D dual-target CAR-T, Autologous CD33/CD123 dual-target CAR-T module, Autologous CD33/CLL1 dual-target CAR-T module, Autologous CD5/CD7 dual-target CAR-T module

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 96 patients

Primary endpoint: Incidence of dose-limiting toxicities (DLTs) by module and dose level; Incidence of Grade 3 or higher cytokine release syndrome (CRS)

Ages: 18 Years to 75 Years

Start date: 2026-03-02 | Est. completion: 2028-02-17

Locations

0 US sites · 1 total

Contact

shan S Lu, Phd | Seni-Lu@beijing-biotech.com | +86 13076790030

Sponsor: Beijing Biotech (INDUSTRY)

Tags

All T-cell lymphomas · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07523555

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.